Skip to Main content Skip to Navigation
Conference papers

PAPP-A and the IGF system

Abstract : Firstly discovered as a placental protein present abundantly in the circulation of pregnant women, pregnancy-associated plasma protein-A (PAPP-A) is widely expressed in multiple tissues. PAPP-A is a metalloproteinase that is able to specifically cleave three insulin-like growth factor binding proteins (IGFBPs): IGFBP-2, -4 and -5. PAPP-A binds tightly to glycosaminoglycans present on the surface of cells, thus functioning within tissues as a growth-promoting enzyme, releasing bioactive IGF in close proximity to the IGF receptor. Pro-MBP and stanniocalcin-2 (STC2) appear to be the main inhibitors of PAPP-A activity, by forming a covalent complex with the protease. According to in vivo experiments, IGFBP-4 is believed to be the main PAPP-A substrate to regulate IGF bioavailability. The regulation of PAPP-A includes transcriptional control of its gene, competing reactions with other IGFBPs potentially sequestering IGF from IGFBP-4 and hence antagonizing PAPP-A-mediated IGF activation, and proteolytic inhibition of PAPP-A. Finally, PAPP-A may serve as a therapeutic target to indirectly inhibit IGF signalling in tissues where this is driven by increased PAPP-A activity. By taking advantage of the intricate interaction between PAPP-A and IGFBP-4, highly specific and selective inhibition of PAPP-A is possible.
Document type :
Conference papers
Complete list of metadata
Contributor : Migration Prodinra Connect in order to contact the contributor
Submitted on : Wednesday, June 3, 2020 - 7:08:53 AM
Last modification on : Tuesday, January 11, 2022 - 5:56:16 PM




Philippe Monget, Claus Oxvig. PAPP-A and the IGF system. 59. Journées Internationales d’Endocrinologie Clinique, Société Française d'Endocrinologie (SFE). FRA., Jun 2016, Paris, France. ⟨10.1016/j.ando.2016.04.015⟩. ⟨hal-02744177⟩



Les métriques sont temporairement indisponibles